Cargando…

Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis

We experienced two cases of hepatitis C virus (HCV) eradication failure in patients with a history of non-responsiveness to previous treatments with direct-acting antiviral agents (DAAs) who were subsequently treated with the combination of glecaprevir and pibrentasvir (GLE/PIB). Direct sequencing a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sano, Tomoya, Akuta, Norio, Suzuki, Fumitaka, Kasuya, Kayoko, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Saitoh, Satoshi, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Kobayashi, Mariko, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794189/ https://www.ncbi.nlm.nih.gov/pubmed/31178495 http://dx.doi.org/10.2169/internalmedicine.2604-18

Ejemplares similares

Fulminant Hepatitis due to de novo Hepatitis B after Cord Blood Transplantation Rescued by Medical Treatment
por: Sano, Tomoya, et al.
Publicado: (2020)

The Lack of Hepatocyte Steatosis in Adult-onset Type II Citrullinemia Patients as Assessed by 7-year Interval Paired Biopsies
por: Suzuki, Hiroyuki, et al.
Publicado: (2019)

Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome
por: Fujiyama, Shunichiro, et al.
Publicado: (2017)

New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease
por: Kawamura, Yusuke, et al.
Publicado: (2017)

Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals
por: Akuta, Norio, et al.
Publicado: (2023)

Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma
por: Akuta, Norio, et al.
Publicado: (2016)

Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan
por: Akuta, Norio, et al.
Publicado: (2018)

SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology
por: Akuta, Norio, et al.
Publicado: (2020)

Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease
por: Akuta, Norio, et al.
Publicado: (2019)

Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD
por: Akuta, Norio, et al.
Publicado: (2019)

Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study
por: Fujiyama, Shunichiro, et al.
Publicado: (2021)

Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir
por: Hosaka, Tetsuya, et al.
Publicado: (2021)

PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD
por: Akuta, Norio, et al.
Publicado: (2021)

Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease
por: Iritani, Soichi, et al.
Publicado: (2020)

Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies
por: Akuta, Norio, et al.
Publicado: (2017)

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis
por: Kuwano, Toru, et al.
Publicado: (2018)

Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease
por: Akuta, Norio, et al.
Publicado: (2022)

Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years
por: Kajiwara, Akira, et al.
Publicado: (2020)

Transcatheter Arterial Chemotherapy with Miriplatin for Hepatocellular Carcinoma Patients with Chronic Renal Failure: Report of Three Cases
por: Imai, Norihiro, et al.
Publicado: (2013)

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib
por: Kasuya, Kayoko, et al.
Publicado: (2020)

Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study
por: Akuta, Norio, et al.
Publicado: (2022)

Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan
por: Akuta, Norio, et al.
Publicado: (2016)

Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver
por: Ogasawara, Nobuhiko, et al.
Publicado: (2019)

Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection
por: Masaki, Keiichi, et al.
Publicado: (2015)

Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment
por: Muraishi, Nozomu, et al.
Publicado: (2021)

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir
por: Suzuki, Fumitaka, et al.
Publicado: (2014)

The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis
por: Muraishi, Nozomu, et al.
Publicado: (2023)

Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma
por: Kawamura, Yusuke, et al.
Publicado: (2023)

What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study
por: Kawamura, Yusuke, et al.
Publicado: (2013)

New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan
por: Kawamura, Yusuke, et al.
Publicado: (2015)

Cholangiolocellular Carcinoma in a Young Patient Who Showed Sustained Virological Response after Treatment for Hepatitis C Virus Infection
por: Osawa, Mitsutaka, et al.
Publicado: (2017)

Two Cases of Advanced Hepatocellular Carcinoma Who Responded Well to the Combination of Durvalumab Plus Tremelimumab After Disease Progression During Atezolizumab Plus Bevacizumab Therapy Under Bevacizumab Withdrawal
por: Kawamura, Yusuke, et al.
Publicado: (2023)

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection
por: Toyoda, Hidenori, et al.
Publicado: (2017)

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
por: Chayama, Kazuaki, et al.
Publicado: (2017)

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
por: Kumada, Hiromitsu, et al.
Publicado: (2017)

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
por: Kumada, Hiromitsu, et al.
Publicado: (2017)

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts
por: Feld, Jordan J., et al.
Publicado: (2022)

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection
por: Liu, Xiaoqing, et al.
Publicado: (2021)

Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases
por: Sugiura, Ayumi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hs426r6k2v3kkktuil6ndruvh3